Remegen
RemeGen Co Ltd is a Chinese commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel biological therapies for autoimmune diseases, oncology, and ophthalmology. The company's antibody-drug conjugate and fusion protein platform has generated key approved therapies including telitacicept for autoimmune disorders and disitamab vedotin for solid tumors. Its R&D operations center on targeted biologics, novel antibody constructs, and specialized clinical trials across China and global markets. Principal revenue is generated from direct commercial sales of approved biologic therapies in Mainland China, alongside upfront collaboration milestone payments and international licensing royalties. RemeGen is a prominent biopharmaceutical innovator in China, holding strategic clinical co-development partnerships with international biopharmaceutical firms. Headquartered in Yantai, China, the company's common stock is dual-listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange STAR Market.
14 of the funds FundTelligence covers report a position in Remegen.
- Legal name
- Remegen Co. Ltd.
- Sector
- Health Care
- Country
- China
- Funds holding it
- 14
Funds holding Remegen
- Nordea Emerging Markets Enhanced — Nordea Funds · 0.05 % (full portfolio disclosed, September 2026)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.02 % (full portfolio disclosed, June 2026)
- Mercer Passive Emerging Markets Equity Fund — Mercer · 0.02 % (full portfolio disclosed, December 2025)
- Danske Invest Global Emerging Markets Index Restricted — Danske Invest · 0.02 % (full portfolio disclosed, July 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.02 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.02 % (full portfolio disclosed, October 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, September 2026)
- DNB Emerging Markets Index — DNB · 0.01 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 14 funds holding it.